You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 24, 2025

Profile for Norway Patent: 20081464


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Norway Patent: 20081464

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,977,488 Aug 11, 2028 Phathom VOQUEZNA TRIPLE PAK amoxicillin; clarithromycin; vonoprazan fumarate
7,977,488 Aug 11, 2028 Phathom VOQUEZNA DUAL PAK amoxicillin; vonoprazan fumarate
7,977,488 Aug 11, 2028 Phathom VOQUEZNA vonoprazan fumarate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name
96https://www.drugpatentwatch.com/inc/modules/tools/ai_gpt_report.php?dashboard=international§ion=patent&query=Norway+drug+patent+NO20081464&subsorpreview=preview

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.